Uprosertib is an investigational small molecule inhibitor targeting the Akt signaling pathway, which plays a key role in cell survival, proliferation, and metabolism. It is primarily explored in oncology for its potential to suppress tumor growth in cancers with hyperactive PI3K/Akt/mTOR pathways. Uprosertib has shown promise in preclinical and clinical studies for treating solid tumors, including breast, ovarian, and prostate cancers, especially those with PTEN deficiency or PIK3CA mutations. It is often studied in combination with other anticancer agents, such as hormone therapies or chemotherapy, to enhance efficacy and overcome resistance. Its application is focused on targeted cancer therapy where Akt activation contributes to disease progression.